Bruce Montgomery - Cytodyn Independent Director
| CYDY Stock | USD 0.16 0.01 6.67% |
Director
Dr. A. Bruce Montgomery, M.D., was appointed as Independent Director of CytoDyn Inc., effective September 27, 2013. Dr. Montgomery is a prominent biotech entrepreneur with an extensive background in product development and clinical studies. He is currently the Chief Executive Officer of Cardeas Pharma Corporationrationration, a biotechnology firm focused on treatment of multidrug resistant bacteria causing pneumonia in patients on ventilation. Before joining Cardeas Pharma Corporation in 2010, Dr. Montgomery founded and was the Chief Executive Officer of Corus Pharma, Inc., a development stage pharmaceutical company, from 2001 until 2006. In 2006, Gilead acquired Corus Pharma, Inc., and Dr. Montgomery continued at Gilead, serving as Senior Vice President, Respiratory Therapeutics, from 2006 until 2010. He previously held positions in clinical development with PathoGenesis Corporation and Genentech. Dr. Montgomery is a director of Alder BioPharmaceuticals, Inc., a NASDAQ listed company, and a Trustee for the Washington State Life Sciences Discovery Fund. He has previously served on the boards of ZymoGenetics, Inc., a NASDAQ listed company until its acquisition in 2010, Pacific Science Center, and the Washington Biotechnology Biomedical Association since 2013.
| Age | 62 |
| Tenure | 11 years |
| Phone | 360 980 8524 |
| Web | https://www.cytodyn.com |
Cytodyn Management Efficiency
The company has return on total asset (ROA) of (1.4819) % which means that it has lost $1.4819 on every $100 spent on assets. This is way below average. Cytodyn's management efficiency ratios could be used to measure how well Cytodyn manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Stephen Glover | PDS Biotechnology Corp | N/A | |
| William Reardon | Madrigal Pharmaceuticals | 68 | |
| David Milligan | Madrigal Pharmaceuticals | 77 | |
| Donald Kufe | Madrigal Pharmaceuticals | 69 | |
| James Daly | Madrigal Pharmaceuticals | N/A | |
| Mason Freeman | Scpharmaceuticals | 66 | |
| Bruce Kovner | Madrigal Pharmaceuticals | 69 | |
| Richard Levy | Madrigal Pharmaceuticals | 60 | |
| Kenneth Bate | Madrigal Pharmaceuticals | 67 | |
| Mette Agger | Scpharmaceuticals | 52 | |
| DeLyle Bloomquist | PDS Biotechnology Corp | 59 | |
| Andrew Saik | PDS Biotechnology Corp | 48 | |
| Minnie BaylorHenry | Scpharmaceuticals | N/A | |
| Gregory Freitag | PDS Biotechnology Corp | 56 | |
| Abhay Gandhi | Scpharmaceuticals | 52 | |
| Scott Morenstein | Madrigal Pharmaceuticals | 38 | |
| Richard Sykes | PDS Biotechnology Corp | 76 | |
| Paul Friedman | Madrigal Pharmaceuticals | 75 | |
| Robert Wilson | Madrigal Pharmaceuticals | 75 | |
| Frederick Craves | Madrigal Pharmaceuticals | 72 | |
| James Loughlin | PDS Biotechnology Corp | 75 | |
Management Performance
| Return On Asset | -1.48 |
Cytodyn Leadership Team
Elected by the shareholders, the Cytodyn's board of directors comprises two types of representatives: Cytodyn inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cytodyn. The board's role is to monitor Cytodyn's management team and ensure that shareholders' interests are well served. Cytodyn's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cytodyn's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Bernie PMP, VP Operations | ||
| Denis Burger, Vice Chairman and Chief Science Officer | ||
| Scott Kelly, Chairman of the Board | ||
| Nitya Ray, CTO and Head of Process Sciences, Manufacturing & Supply Chain | ||
| Carl Dockery, Director | ||
| Bruce Montgomery, Independent Director | ||
| Michael Mulholland, CFO, Treasurer, Corporate Secretary | ||
| David Welch, Director | ||
| Antonio CPA, Treasurer CFO | ||
| Nader Pourhassan, CEO and President and Director | ||
| Richard Pestell, Vice Chairman of the Board and Chief Medical Officer | ||
| Cyrus MBA, President | ||
| George Bitar, Head Director | ||
| Marek Ciszewski, Managing Director | ||
| Jordan Naydenov, Independent Director | ||
| Anthony Caracciolo, Chairman of the Board | ||
| Robert Schatz, Managing Director | ||
| Gregory Gould, Independent Director | ||
| Kush Dhody, VP Operations | ||
| Cristina Leon, Investors | ||
| Michael Klump, Independent Director |
Cytodyn Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Cytodyn a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -1.48 | |||
| Current Valuation | 286.7 M | |||
| Shares Outstanding | 832.97 M | |||
| Shares Owned By Insiders | 7.91 % | |||
| Shares Owned By Institutions | 0.06 % | |||
| Price To Earning | (3.14) X | |||
| Price To Book | 1,066 X | |||
| Price To Sales | 1,174 X | |||
| Revenue | 266 K | |||
| Gross Profit | (73.28 M) |
Pair Trading with Cytodyn
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cytodyn position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cytodyn will appreciate offsetting losses from the drop in the long position's value.Moving against Cytodyn OTC Stock
| 0.42 | AA | Alcoa Corp Financial Report 17th of July 2024 | PairCorr |
The ability to find closely correlated positions to Cytodyn could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cytodyn when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cytodyn - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cytodyn to buy it.
The correlation of Cytodyn is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cytodyn moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cytodyn moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cytodyn can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cytodyn. Also, note that the market value of any otc stock could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment. Note that the Cytodyn information on this page should be used as a complementary analysis to other Cytodyn's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Complementary Tools for Cytodyn OTC Stock analysis
When running Cytodyn's price analysis, check to measure Cytodyn's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cytodyn is operating at the current time. Most of Cytodyn's value examination focuses on studying past and present price action to predict the probability of Cytodyn's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cytodyn's price. Additionally, you may evaluate how the addition of Cytodyn to your portfolios can decrease your overall portfolio volatility.
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Fundamental Analysis View fundamental data based on most recent published financial statements |